NCT05615636

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: M.D. Anderson Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

Detailed description

Primary Objectives: To determine the safety of mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide in relapsed/refractory NHL. To determine the best overall response rate (ORR) of the combination of mosunetuzumab, with polatuzumab vedotin, tafasitamab, and lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma. Secondary Objectives: To determine the complete response rate, duration of response, progression free survival, and overall survival in patients with DLBCL following treatment with of mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide. To evaluate changes in immune effector cells and the tumor microenvironment following treatment with of mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide.

Conditions

• Hodgkin Lymphoma
• B-Cell Lymphoma
• Relapsed B-cell NHL

Interventions

Type	Name	Description
DRUG	Mosunetuzumab	Given by IV (vein)
DRUG	Polatuzumab vedotin	Given by IV (vein)
DRUG	Tafasitamab	Given by IV (vein)
DRUG	Lenalidomide	Given by PO

Timeline

• Start date: 2023-04-28
• Primary completion: 2027-08-19
• Completion: 2027-08-19
• First posted: 2022-11-14
• Last updated: 2026-03-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study